AVITA Medical Inc
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AVITA Medical, Inc. | |
| (Registrant) | |
| Date: February 13, 2025 | /s/ James Corbett |
|---|---|
| James Corbett | |
| Chief Executive Officer (Principal Executive Officer) | |
| Date: February 13, 2025 | /s/ David O’Toole |
| David O’Toole | |
| Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ James Corbett | Chief Executive Officer and Director | February 13, 2025 |
| James Corbett | (Principal Executive Officer) | |
| /s/ David O’Toole | Chief Financial Officer | February 13, 2025 |
| David O’Toole | (Principal Financial and Accounting Officer) | |
| /s/ Lou Panaccio | Chairman of the Board of Directors | February 13, 2025 |
| Lou Panaccio | ||
| /s/ Jeremy Curnock Cook | Director | February 13, 2025 |
| Jeremy Curnock Cook | ||
| /s/ Suzanne Crowe | Director | February 13, 2025 |
| Suzanne Crowe | ||
| /s/ Jan Stern Reed | Director | February 13, 2025 |
| Jan Stern Reed | ||
| /s/ Robert McNamara | Director | February 13, 2025 |
| Robert McNamara | ||
| /s/ Cary Vance | Director | February 13, 2025 |
| Cary Vance | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||
| Report of Independent Registered Public Accounting Firm | (PCAOB ID Number 248) | F-2 |
|---|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 | |
| Consolidated Statements of Operations for the Years-Ended December 31, 2024 and 2023 | F-4 | |
| Consolidated Statements of Comprehensive Loss for the Years-Ended December 31, 2024 and 2023 | F-5 | |
| Consolidated Statements of Stockholders’ Equity for the Years-Ended December 31, 2024 and 2023 | F-6 | |
| Consolidated Statements of Cash Flows for the Years-Ended December 31, 2024 and 2023 | F-7 | |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.